AbstrAct
Human male reproductive disorders (cryptorchidism, hypospadias, testicular cancer and low sperm counts) are common and some may be increasing in incidence worldwide. These associated disorders can arise from subnormal testosterone production during fetal life. This has resulted in a focus on in-utero environmental influences that may result in reproductive effects on the offspring in later life. Over recent years, there has been a dramatic increase in the scientific literature describing associations between in-utero environmental exposures (eg, industrial chemicals and pharmaceuticals) and subsequent reproductive outcomes in male offspring. This includes studies investigating a potential role for inutero analgesic exposure(s) on the fetal testis; however, providing definitive evidence of such effects presents numerous challenges. In this review, we describe an approach to assessing the potential clinical relevance of in-utero (and postnatal) environmental exposures on subsequent male reproductive function using exposure to the analgesic paracetamol as an example.
MAle reproductive disorders And testiculAr dysgenesis syndroMe
From the mid 1900s to the present date, many studies have reported evidence for an increasing secular trend in the most common male reproductive abnormalities including hypospadias, cryptorchidism, low sperm counts [1] [2] [3] [4] [5] and testicular germ cell cancer (TGCC). [6] [7] [8] [9] [10] Over the past 30 years, the incidence of TGCC has increased substantially 10 and epidemiological studies predict that the incidence in Europe will increase by a further 24% by 2025. 9 11 The term 'testicular dysgenesis syndrome' (TDS) is often used to describe this group of individual disorders due to their frequent association and their relationship to impaired androgen production/action during fetal life. Genetic causes of impaired androgen action include androgen insensitivity syndrome (AIS), caused by a mutation in the androgen receptor in XY individuals, which results in undermasculinisation of the external genitalia, which can result in a typical female appearance in the complete (CAIS) form. AIS also includes features consistent with TDS (hypospadias, cryptorchidism, infertility and an increased risk of TGCC). 12 13 Although it is clear that many TDS disorders can arise as a result of genetic abnormalities, there is increasing evidence that in-utero environmental factors (including lifestyle and chemical exposures) may also play a role (figure 1). 3 14-16 Studies in rodents have demonstrated that perturbation of androgen production/action during fetal life results in the development of TDS disorders in male offspring. [17] [18] [19] [20] [21] [22] These studies involve in-utero exposure to a plasticising agent (Di-n-butyl phthalate) which results in subsequent cryptorchidism, hypospadias, impaired spermatogenesis and primary hypogonadism. Crucially, there is a critical window of sensitivity in fetal life, termed the 'masculinisation programming window' (MPW), during which the subsequent development of these disorders may be programmed by lack of androgen production or action. 19 The MPW has been shown to occur between embryonic day (e)15.5-e18.5 in rats and has been estimated to correspond to 8-14 weeks of gestation in humans. 19 22 One of the challenges in understanding the development of these disorders in humans has been the assessment of fetal androgen exposure in male offspring. Measurement of anogenital distance (AGD), which is sexually dimorphic, can be used as a biomarker/read-out of fetal androgen exposure, and thus are a proxy for anti-androgenic effects of in-utero exposures [23] [24] [25] that can be used throughout life. 25 26 AGD is reduced in boys presenting during the neonatal period with cryptorchidism and/or hypospadias, 27 and in adulthood, AGD has been shown to be positively associated with semen quality 28 29 and serum testosterone. 23 It should be emphasised that althoughmeasuring AGD can be used for carefully conducted population-based studies, technical difficulties, in terms of accuracy of measurement, reproducibility and time required to conduct this examination, limit its utility for clinical assessment of individuals.
The association between events that occur during fetal life and the development of male reproductive disorders has resulted in a large number of epidemiological and experimental studies investigating the potential role for in-utero environmental (chemical and pharmaceutical) exposures. Recent studies have described a potential role for analgesics in the development of these disorders. [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] To describe the potential effects of in-utero exposure to analgesics on male reproductive development, we will first discuss in detail the development of the testis from fetal life, focusing on cellular events that determine testosterone production and germ cell development. We will then briefly describe the approach to assessing in-utero environmental exposures before describing in detail the potential effects of paracetamol (the most commonly used analgesic worldwide) exposure during pregnancy,
review
Assessing the impact of in-utero exposures: potential effects of paracetamol on male reproductive development review on male reproductive health in the offspring and subsequent generation(s).
testiculAr developMent And function during fetAl And eArly postnAtAl life formation of the testis
To understand the potential for in-utero exposures to affect the developing testis, it is important to understand testicular cellular development and function during fetal life and the early postnatal period (figure 2). Primordial germ cells emerge at 4-5 weeks postconception in the human and migrate from the yolk sac into the genital ridge where they become known as gonocytes. 41 Interaction between gonocytes and the stromal microenvironment, along with the presence of a single transcription factor coded by the Y chromosome, sex-determining region Y protein (SRY), determines gonadal sex. Following SRY expression, gonadal somatic cells, arising from the coelomic epithelium, begin to differentiate into Sertoli cells (SC). 42 SC aggregate in a layer around gonocytes, thus forming the seminiferous cords at approximately 6-7 gestational weeks in the human (or e13 in the mouse). 43 44 The seminiferous cords separate the seminiferous epithelium, consisting solely of germ cells and SC, from the interstitial compartment, which includes the testosterone-secreting fetal Leydig cell population. 45 sertoli cell development and function SC play a vital role in supporting spermatogenesis in the adult testis. The total number of SC in adulthood determines final testis size, number of germ cells and maximum sperm output. [46] [47] [48] However, SC also have important functions in fetal life including secretion of anti-Müllerian hormone, necessary for regression of the Müllerian ducts, and factors (eg, Desert Hedgehog) which play a role in fetal Leydig cell differentiation. [49] [50] [51] [52] SC proliferation in humans occurs during fetal and neonatal life followed by a quiescent period until the second proliferative wave around puberty. 48 The switch from prepuberty to puberty triggers the final maturation from proliferative immature SC to non-mitotic mature SC capable of supporting spermatogenesis (figure 2). Rodent studies have indicated that prenatal exposure to plasticising chemicals known as phthalates can arrest SC development in their immature state, thus interfering with spermatogenesis 18 21 and foci of immature SC are also a common feature in infertile men with azoospermia and other TDS disorders. 21 53 germ cell development and fertility During fetal and early postnatal life, the germ cells differentiate from gonocytes into spermatogonia during which they cease to express pluripotency pre-malignant markers (eg, OCT4 and Nanog) and begin to express germ cell-specific spermatogonial proteins (dDX4, MAGE-A4), a process that occurs figure 1 In-utero factors proposed to predispose to testicular dysgenesis syndrome (TDS) disorders. Many lifestyle, genetic and environmental factors during fetal life have been postulated to lead to the development of TDS disorders in male offspring, although with variable (and in some cases limited) sources of evidence. review asynchronously in humans from late second trimester to ~6 months postnatally. 54 This period of germ cell development is important in establishing the spermatogonial stem cell pool for future fertility. In addition, failure of gonocytes to differentiate into spermatogonia during fetal/early postnatal life is thought to result in germ cell neoplasia in-situ (GCNIS), the pre-malignant TGCC in adulthood 55 ( figure 2 ). In addition to the increased risk of TGCC, individuals with TDS disorders may also exhibit dysgenetic areas in the testis in which germ cells are lost and seminiferous tubules become Sertoli cell-only. Therefore, environmental influences that impair germ cell development during fetal and early postnatal life may result in reduced fertility and/ or the development of TGCC. 16 
leydig cell development and function
Leydig cells (LC) are essential for endocrine function of the testis as they produce the steroid hormone testosterone. Testosterone is primarily required for fetal masculinisation (including testicular descent), pubertal development and spermatogenesis. LC development in the human is considered a 'triphasic event', as demonstrated by the peaks in plasma testosterone levels across the life course that coincide with the development of separate lineages of LC (figure 2). A fetal LC population is present from 6 weeks gestation in humans (e12.5 in the mouse).
56-59 By 2-3 months of postnatal life, a neonatal population is evident, responsible for the so-called 'mini-puberty' 60 and finally, an adult LC population arises at puberty and remains throughout adulthood. 61 Placental human chorionic gonadotrophin (hCG) initially stimulates testosterone production from the fetal LC and insufficiency in the former is associated with hypospadias and cryptorchidism, 62 whereas during the neonatal period, luteinising hormone (LH)is responsible for stimulating the peak in plasma testosterone levels. 63 64 In rodents, perturbations of fetal testosterone production (eg, due to phthalate exposure) may result in some TDS disorders, including Leydig cell hyperplasia 62 and has also been shown to be associated with primary hypogonadism/compensated LC failure in adulthood. 20 21 Insulin-like factor 3 (Insl3) is another hormone produced by the Leydig cell which, like testosterone, plays a crucial role in testicular descent. Perturbations in Insl3 during the fetal period can also result in cryptorchidism in rodents. 65 66 Assessing the iMpAct of environMentAl exposures on huMAn heAlth Studies aimed at investigating the impact of environmental exposures on human health largely consist of epidemiological studies in human populations and experimental animal studies. While epidemiological evidence can demonstrate associations between exposures and occurrence of a condition, experimental studies can imply causation and demonstrate potential mechanisms. Critical assessment of the literature on effects of environmental exposures must take into account the strengths and limitations of these approaches (box 1). We will describe the epidemiological and experimental evidence in relation to paracetamol exposure and the development of male reproductive disorders, highlighting some of the factors that need to be considered in order to critically assess such studies.
effects of exposure to pArAcetAMol on MAle reproductive heAlth Maternal use of paracetamol during pregnancy
Avoidance of pain and fever during pregnancy is important for fetal and maternal health, and analgesics play an important role in the treatment of pain and fever during pregnancy. In a large study of pregnant women from Europe, USA and Australia (n=9459), 81.2% reported taking over-the-counter (OTC) medicines. 67 It is reported that >50% of pregnant women in USA take OTC analgesics, including paracetamol. 68 69 Studies in UK of self-reported medication use have shown that paracetamol review is the most commonly used OTC medication during pregnancy, with 36% of pregnant women reporting paracetamol intake during the first trimester (n=465/1305) 70 and 54% during the first 20 weeks of gestation. 71 In a similar Danish study, 47% of mothers reported taking paracetamol at some point during their pregnancy. 30 Paracetamol readily crosses the placental barrier with a mean half-life of approximately 3 hours 72 73 and its serum concentration is equivalent between mother and fetus following an oral therapeutic dose (1 g). 74 The number of epidemiological and experimental studies into the potential relationship between analgesic exposure and male reproductive disorders have been increasing over recent years. Epidemiological studies have reported associations between maternal use of analgesics and cryptorchidism in resulting male offspring 30 32 33 75 ; however, this is not consistent across all studies. 34 Where associations exist, they appear to be restricted to exposure during the second trimester or following prolonged exposure. 35 The timing of exposure in relation to the critical period for programming male reproductive development is likely to be important. One study has reported an association between cryptorchidism and paracetamol exposure during the human MPW (estimated to be 8-14 gestational weeks 19 ); however importantly, this was only statistically significant for prolonged exposure of >4 weeks. 32 The reported association between exposure to paracetamol and cryptorchidism could be explained by a reduction in androgen (testosterone) production by the human fetal testis, and AGD has been shown to represent an 'indirect' postnatal readout of androgen exposure during fetal life. 24 A recent prospective birth cohort study showed that 40% of women reported using paracetamol during the first 28 weeks of pregnancy. 36 Exposure to a mixture of mild analgesics, including paracetamol and non-steroidal anti-inflammatory drugs (NSAIDS),) was negatively associated with AGD in male infants (n=20; 3 months) which suggests reduced androgen signalling during fetal life.
However, these results do not show a paracetamol-only induced effect and this may highlight the importance of exposure to 'mixtures' potentially resulting in additive effects which may be more representative of analgesic intake during pregnancy. 36 A similar study (n=434 male infants) reported an association between paracetamol exposure and reduced AGD from birth to 2 years which was independent of body size 37 and interestingly, this association was limited to paracetamol exposure during the proposed human MPW (ie, first trimester). Importantly, all of the above epidemiological studies are based on self-reporting of analgesic use, determined in most cases by the use of retrospective questionnaires. The possibility of inaccurate recall or recall bias and lack of direct measurements of analgesic exposure are important limitations of these studies. experimental approach to assessing the effect of paracetamol exposure during fetal life on male reproductive function A variety of experimental approaches have been used to determine the effect of paracetamol exposure on the fetal testis, particularly in relation to testosterone production. This includes in-vivo approaches in pregnant rodents 30 38 76 77 and in-vitro studies using fetal testis tissues from rodents 30 78 and humans. 39 Recently, a xenografting approach has been developed which can assess the effects of exposures on the human fetal testis in a more physiological manner than can be achieved in vitro. 38 To investigate potential paracetamol-induced effects during fetal life, pregnant rats were exposed to doses of 150, 250 or 350 mg/kg/day from e13 to e21. AGD was reduced in male offspring compared with untreated controls 30 with similar effects on AGD described in other studies. 38 77 However, a recent study using the same regimen as described above (350 mg/kg/day from e13 to e21) did not demonstrate a significant effect on AGD. 76 The timing of exposure in these studies coincides with the MPW; however, the doses (150-350 mg/kg/day) used are higher than therapeutic doses (~60 mg/kg/day) to which humans are usually exposed. 38 There are also likely to be large differences in the pharmacokinetics and metabolism of these agents in rodents compared with humans, making direct correlations from dose effects between species challenging.
In-vitro paracetamol exposure studies have also been described using fetal rat testis explants (e14.5) cultured for 3 days in media containing paracetamol (1 µM). 30 78 This resulted in a significant reduction in testosterone production, even at a concentration of 1 µM, which is well below the therapeutic concentration described in human plasma (65-130 µM) following paracetamol ingestion. 30 This could suggest that in-vitro effects may underestimate the effects that occur in humans; however, it should be emphasised that circulating paracetamol levels may not be a direct indicator of intratesticular levels. In addition, the in-vitro models cannot mimic the pharmacokinetics, including peak and trough concentrations that occur in vivo.
The majority of experimental studies in rodents suggest a negative association between paracetamol exposure and fetal androgen production. This has prompted subsequent in-vitro studies using human fetal testis tissue. Exposure of first trimester testis (8-12 weeks gestation) to paracetamol (10 µM) for 1-3 days did not alter testosterone production compared with vehicle-exposed controls. 39 The differences between the results of the rodent and human in-vitro studies may relate to differences in the suitability of the in-vitro system or the timing of exposure in relation to the stage of development (including the timing of the MPW) between these two species. 39 In-vitro culture conditions cannot replicate normal box 1 Key points to consider when assessing epidemiological and experimental studies relating to the effects of environmental exposures on male reproductive development epidemiological ► Study design-descriptive, case-control or experimental, relevant population. ► Exposure-measured directly (agent) or indirectly (questionnaire, proxy exposure). ► Effect-direct effect (eg, cryptorchidism) or indirect (AGD). ► Other-mechanistic plausibility for effects. experimental ► Model-species, experimental system (eg, in-vivo, in-vitro and ex-vivo). ► Agent-same agent or similar class/compound, metabolism of agent. ► Dosing-dose equivalent (eg, serum/in-vitro concentrations), timing and duration. ► Effect-direct effect (eg, cryptorchidism) or proxy for clinical condition (AGD). ► Mechanism-for example, effect on signalling pathways (including rescue). review human testosterone production or the in-vivo environment.
To circumvent some of these limitations, an ex-vivo xenograft approach can be undertaken to investigate potential paracetamol-induced effects on the human fetal testis. 79 80 Using this system, human fetal testis tissue pieces (n=5; 14-20 weeks gestation) were grafted subcutaneously under the dorsal skin of castrate host nude mice. Paracetamol was then administered orally to the host animal according to a therapeutic regimen (20 mg/kg; three times a day), resulting in a significant reduction (45%) in host serum testosterone after 7 days of paracetamol exposure, while a single day of exposure did not affect testosterone production. 38 Interestingly, plasma paracetamol concentrations, measured 1 hour after the final dose, 38 were significantly lower compared with post-therapeutic levels reported in pregnant women 72 suggesting that the effects on testosterone can occur at clinically relevant paracetamol doses/ exposures. The effect of prolonged paracetamol exposure of xenografts 38 is in contrast to the results obtained from in-vitro culture of human fetal testis tissue. 39 This could be due to the method of delivery (media versus oral administration), timing of exposure in vitro (8-12 weeks gestation) compared with xenografts (14-20 weeks gestation), the relative dosage, length of exposure or difference in metabolism between in-vivo and in-vitro studies. Further limitations of both the in-vitro and xenograft systems include the lack of a feto-placental unit, although it has been demonstrated that paracetamol is able to cross the placenta and enter the fetal circulation in similar concentrations to maternal plasma. 72 73 Overall, the results of the experimental studies suggest that exposure to paracetamol during fetal life may lead to a reduction in testosterone production in humans, although direct correlation between the degree and duration of reduced testosterone and the potential to develop male reproductive disorders cannot be made from these studies. While the majority of circulating paracetamol in humans comes from ingestion of paracetamol-containing medications, an alternative source of paracetamol has also recently been described. The industrial chemical aniline, which is found in a wide variety of manufactured products for example, pharmaceuticals, cosmetics and cigarette smoke, has been shown to be rapidly metabolised to paracetamol inside the body. 81 82 In-vivo studies involving in-utero exposure of male mice to aniline have shown similar fetal antiandrogenic effects to those described for exposure to paracetamol. 77 It is known that analgesics, including paracetamol, can inhibit prostaglandin synthesis. 83 During fetal life, germ cells have been shown to be prostaglandin targets 84 85 indicating that germ cells may also be susceptible to analgesic-induced changes, which in turn may alter GC development and fertility in the offspring. To investigate this, in-vivo studies of in-utero paracetamol exposure have been conducted in rodents. 85 86 In one study, pregnant rats were exposed to paracetamol (350 mg/ kg/day) from e15.5 to e18.5, which resulted in altered germ cell development in both sexes of offspring. 85 In males, there was an accelerated loss of expression of a pluripotency marker (OCT4), suggesting germ cell differentiation from gonocyte to spermatogonia had occurred prematurely. It is interesting to note that the effects on germ cell differentiation in F1 males occur during the MPW, a critical period for male reproductive development. 21 85 In F1 females, there was a delay in meiotic entry in oogonia. Following in-utero paracetamol exposure, adult female offspring had reduced ovary size and exhibited reduced litter size in adulthood, while no reproductive effects were seen in adult males, suggesting a potential compensatory mechanism between fetal life and adulthood. 85 In another study, exposure of pregnant rats to a much lower dose of paracetamol (50 mg/kg/day) from 7 days postconception to birth resulted in a reduction in follicle number in female offspring at 2 months postnatally and also a reduction in pups per litter at 6 months of age. 86 During fetal life, germ cells undergo epigenetic reprogramming 87 which suggests that any perturbations to germ cells during this period could have intergenerational effects. The potential for such effects occurring following in-utero paracetamol exposure was investigated in a recent study in which paracetamol-exposed (male anPostnatald female) mice were mated with a non-exposed partner. The subsequent F2 females had reduced ovary weight (as previously described) and reduced number of primordial follicles, while F2 males did not appear to have any demonstrable germ cell effects. 85 effects of postnatal paracetamol exposure on male reproductive function While the majority of studies have investigated the effect of analgesic exposure on the fetal testis, one study has demonstrated that the adult testis may be susceptible to endocrine perturbations following paracetamol exposure. Explants from human adult testes (average age: 79.8±5.6 years) were cultured in vitro with therapeutically relevant doses of paracetamol for 24 hours, resulting in a significant reduction in testosterone production in the presence of 10 -4 or 10 -5 M paracetamol (30% and 18% reduction, respectively). 88 To date, no studies have been conducted to assess the effect of analgesic use in adult men in terms of testosterone production or testicular function.
Analgesics are also commonly used in paediatrics; however, to our knowledge, there have been no studies investigating the effect of analgesic exposure during the neonatal, infancy or childhood period in terms of later male reproductive function. In addition, the testicular effects of exposures on babies born preterm has not been investigated. Pharmacokinetic studies have shown that based on body weight, neonates have approximately 30% paracetamol clearance capacity compared with adults. [89] [90] [91] Exposure during the neonatal period may be of particular importance given the programmed rise in testosterone during mini-puberty. 64 Whether paracetamol exposure during this period can suppress testosterone and what the implications might be for subsequent reproductive health is unknown, although it is worth pointing out that in individuals with conditions such as hypogonadotropic hypogonadism (in whom there is no rise in testosterone during mini-puberty or at expected time of puberty), testicular function and fertility can be restored with exogenous gonadotrophins. 92 Given the relative quiescence of the HPG axis during the childhood period, it would be anticipated that the potential for antiandrogenic effects of analgesics would not be as important during this period compared with other stages throughout life; however, it is unknown whether exposures can affect Leydig, Sertoli or germ cell development during this period. Further studies are warranted to investigate the effects of exposure to analgesics during postnatal life.
conclusion
Male reproductive disorders are common and some are increasing in incidence. These disorders can be associated and linked to a reduction in testosterone during fetal life. In-utero exposure to environmental agents is likely to play a role in the development of these disorders. In order to assess the potential impact of environmental agents on male reproductive function in humans, careful consideration of study methodology review is required, particularly in relation to the model system and species, in addition to dose, route and duration of exposure. Effects of exposures, for example, reduction in testosterone, must be considered in the context of the potential to result in a subsequent disorder such as cryptorchidism or reduced sperm production/counts. For in-utero paracetamol exposure, epidemiological studies demonstrate associations with cryptorchidism in the offspring, primarily in relation to exposures during the second trimester and prolonged duration of exposure, while experimental studies suggest that paracetamol can reduce testosterone production by the human fetal testis. Based on the current evidence discussed, it cannot be concluded that exposure to paracetamol is a direct cause of male reproductive disorders nor that analgesics should simply be avoided during pregnancy. The importance of managing pain and fever during pregnancy should also be considered for the health of the mother and fetus. As a result, a pragmatic approach is to ensure that where analgesics are deemed to be necessary, that they are used at the minimum therapeutic dose for the shortest possible duration. Future studies should aim to determine the clinical relevance of the findings related to in-utero exposures, in addition to investigating the effects of exposures during postnatal life.
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